Chongqing Zhifei Biological Products Co.,Ltd.
|The predecessor company was integrated into Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), and entered biological products industry.
|Beijing Luzhu Biopharmaceutical Co., Ltd. was founded and the company started the construction of its R&D and manufacturing facilities.
|Chongqing Zhiren Biotech Co., Ltd. was founded, which mainly engages in distribution of biological products and generic drugs.
|The first self-developed product — Meningococcal Group A and C Conjugate Vaccine (MenAC Conj Vaccine) received market approval.
|Self-developed product — Group ACYW135 Meningococcal Polysaccharide Vaccine (MenACYW135 Ps Vaccine) received market approval.
|MenAC Conj Vaccine and MenACYW135 Ps Vaccine launched onto the domestic market.
|Zhifei was restructured into a joint-stock company.
|Zhifei successfully went listed on Chinext, Shenzhen Stock Exchange.
|In 2012, Zhifei launched an independently developed new product - Hib vaccine.
|In 2014, MenAC-Hib, independently-developed by Zhifei, first product of its kind worldwide was launched filling the blank of combination vaccine of meningococcus and Haemophilus influenzae.
In the same year, Zhifei founded Chongqing Zhirui Investment Co., Ltd., an equity investment company, with self-funding and the contribution of Mr. Jiang Rensheng, the controlling shareholder and actual controller of Zhifei, to make presence in a broader biological industry.
|In 2015, Zhifei signed a strategic cooperation agreement with Institut Pasteur of Shanghai of Chinese Academy of Sciences.
|In 2016, Zhifei founded Zhifei Airport (Beijing) International Trade Co., Ltd.
|In 2017, Zhifei renewed its distribution and promotion cooperation agreement with Merck Sharp & Dohme of USA (MSD) to import 4-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 20-45 years.
In 2018, Zhifei signed a supplementary agreement with MSD to import 9-valent Human Papilloma Virus Vaccine (Saccaromyces Cerevisiae) to provide health protection for Chinese women aged 16-26 years.
The Company get completed the clinical and production site verification for its independently developed Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) and Mycobacterium Vaccine (for TB infected population use) and increased the registered capital of its wholly-owned subsidiaries Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. to RMB1,332,156,900 and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. to RMB765 million; Chairman Jiang Rensheng was awarded the honorary title of outstanding builder of socialism with Chinese characteristics.
Recombinant mycobacterium tuberculosis fusion protein (EC, Ekear ®) was issued the drug registration approval document in April;
The recombinant novel coronavirus vaccine (CHO cells) jointly developed by the company and the Institute of Microbiology Chinese Academy of Sciences officially obtained the Clinical Trial Notice of the National Medical Products Administration in June.
On March 10, the novel coronavirus vaccine (CHO cells) jointly developed by Zhifei Longcom and the Institute of Microbiology, Chinese Academy of Sciences, was granted the emergency use license in China. It became the first internationally approved recombinant protein subunit vaccine in the world.